S. Baconnier - Academia.edu (original) (raw)

Papers by S. Baconnier

Research paper thumbnail of New crystal in the pineal gland: characterization and potential role in electromechano-transduction

Research paper thumbnail of Microcrystals of Calcite in the Pineal Gland of the Human Brain

Ferroelectrics, 2002

ABSTRACT A new form of biomineralization has been found in the pineal gland of the human brain. T... more ABSTRACT A new form of biomineralization has been found in the pineal gland of the human brain. The crystals are 10 to 20 w m in length and have well-defined morphologies. Several structure types have been identified using scanning electron microscopy (SEM). Energy dispersive spectroscopy (EDS) showed that the crystals contain only the elements calcium, carbon and oxygen. Selected-area electron diffraction (SAED) and near infrared Raman spectroscopy established that the crystals are calcite. With the exception of the otoconia structure of the inner ear, this is the first report of the presence of non-pathological calcite in the human body. These microcrystals are believed to be responsible for the previously observed second harmonic generation (SHG) in pineal tissue samples and they may also exhibit piezoelectricity, suggesting a unique electromechanical biological transducer mechanism in the human brain.

Research paper thumbnail of Frequency agile materials for tunable microwave electronics

Ceramics International, 2004

Research paper thumbnail of Calcite microcrystals in the pineal gland of the human brain: First physical and chemical studies

Bioelectromagnetics, 2002

Research paper thumbnail of A first-in-man phase I trial of a new monoclonal antibody labelled with yttrium 90 for radioimmunotherapy of relapsed or refractory non resectable synovial-sarcomas

Physica Medica, 2013

ABSTRACT Anti-FZD10 antibody-DTPA-90Y (Anti-FZD10-DTPA-90Y) is a novel radioimmunotherapy treatme... more ABSTRACT Anti-FZD10 antibody-DTPA-90Y (Anti-FZD10-DTPA-90Y) is a novel radioimmunotherapy treatment for synovial-sarcomas (SS) which associates a chimeric monoclonal antibody targeting FZD10 with 90 Yttrium radioisotope (90Y). The expression of FZD10 is observed in SS clinical samples with high frequency, while it is not detected in normal tissues except placenta. Based on pre-clinical data, Anti-FZD10-DTPA-90Y is expected to have potent anti-tumour activity in humans with SS, with little side effects. The objectives of this study were to determine tumour uptake and biodistribution of Anti-FZD10-DTPA, to evaluate the absorbed dose to critical organs and to support the treatment decision.Materials and methodTen patients with relapsed or refractory non resectable SS were enrolled. They received an injection of approximately 185 MBq of 111In-Anti-FZD10-DTPA for pretreatment dosimetric study. Two quantitative imaging protocols have been designed: 2D (based on whole-body gamma-cameras scan) and 3D (based on SPECT/CT). The scans were obtained at different time points: 1-h (without urination), 2 h, 5 h, 24 h, 48 h, 72 h and 144 h after 111In-Anti-FZD10-DTPA injection. The conjugate-view technique was applied to anterior and posterior images after background, scatter and attenuation corrections. The radiation absorbed dose of 90Y-Anti-FZD10-DTPA to heart, lungs, liver, spleen, kidneys, bladder and bone marrow has been evaluated by calculating the cumulated activity in each of these organs from region of interest drawn on planar and SPECT/CT 111In-Anti-FZD10-DTPA imaging. Based on these calculations, and mostly the dose to tumour, the decision to treat with 90Y-Anti-FZD10-DTPA was taken by the scientific committee.ResultsScintigraphic images showed blood vessel activity in arteries and an early uptake in liver persisting over time. Median absorbed doses for 90-yttrium (mGy/MBq) were 3.5, 5.6, 3.8, 2.8, 0.5 to heart, liver, spleen, kidneys and bladder respectively. The uptake in lungs and bone marrow was negligible. No toxicity was observed.Conclusion90Y-Anti-FZD10-DTPA seems to be a well tolerated therapy, with potential efficiency and high tumour specificity. An ancillary study aims to analyze the correlation between predictive dosimetry from 111In imaging and actual dose delivered by the treatment from SPECT/CT and PETC/CT imaging of Yttrium-90.

Research paper thumbnail of New crystal in the pineal gland: characterization and potential role in electromechano-transduction

Research paper thumbnail of Microcrystals of Calcite in the Pineal Gland of the Human Brain

Ferroelectrics, 2002

ABSTRACT A new form of biomineralization has been found in the pineal gland of the human brain. T... more ABSTRACT A new form of biomineralization has been found in the pineal gland of the human brain. The crystals are 10 to 20 w m in length and have well-defined morphologies. Several structure types have been identified using scanning electron microscopy (SEM). Energy dispersive spectroscopy (EDS) showed that the crystals contain only the elements calcium, carbon and oxygen. Selected-area electron diffraction (SAED) and near infrared Raman spectroscopy established that the crystals are calcite. With the exception of the otoconia structure of the inner ear, this is the first report of the presence of non-pathological calcite in the human body. These microcrystals are believed to be responsible for the previously observed second harmonic generation (SHG) in pineal tissue samples and they may also exhibit piezoelectricity, suggesting a unique electromechanical biological transducer mechanism in the human brain.

Research paper thumbnail of Frequency agile materials for tunable microwave electronics

Ceramics International, 2004

Research paper thumbnail of Calcite microcrystals in the pineal gland of the human brain: First physical and chemical studies

Bioelectromagnetics, 2002

Research paper thumbnail of A first-in-man phase I trial of a new monoclonal antibody labelled with yttrium 90 for radioimmunotherapy of relapsed or refractory non resectable synovial-sarcomas

Physica Medica, 2013

ABSTRACT Anti-FZD10 antibody-DTPA-90Y (Anti-FZD10-DTPA-90Y) is a novel radioimmunotherapy treatme... more ABSTRACT Anti-FZD10 antibody-DTPA-90Y (Anti-FZD10-DTPA-90Y) is a novel radioimmunotherapy treatment for synovial-sarcomas (SS) which associates a chimeric monoclonal antibody targeting FZD10 with 90 Yttrium radioisotope (90Y). The expression of FZD10 is observed in SS clinical samples with high frequency, while it is not detected in normal tissues except placenta. Based on pre-clinical data, Anti-FZD10-DTPA-90Y is expected to have potent anti-tumour activity in humans with SS, with little side effects. The objectives of this study were to determine tumour uptake and biodistribution of Anti-FZD10-DTPA, to evaluate the absorbed dose to critical organs and to support the treatment decision.Materials and methodTen patients with relapsed or refractory non resectable SS were enrolled. They received an injection of approximately 185 MBq of 111In-Anti-FZD10-DTPA for pretreatment dosimetric study. Two quantitative imaging protocols have been designed: 2D (based on whole-body gamma-cameras scan) and 3D (based on SPECT/CT). The scans were obtained at different time points: 1-h (without urination), 2 h, 5 h, 24 h, 48 h, 72 h and 144 h after 111In-Anti-FZD10-DTPA injection. The conjugate-view technique was applied to anterior and posterior images after background, scatter and attenuation corrections. The radiation absorbed dose of 90Y-Anti-FZD10-DTPA to heart, lungs, liver, spleen, kidneys, bladder and bone marrow has been evaluated by calculating the cumulated activity in each of these organs from region of interest drawn on planar and SPECT/CT 111In-Anti-FZD10-DTPA imaging. Based on these calculations, and mostly the dose to tumour, the decision to treat with 90Y-Anti-FZD10-DTPA was taken by the scientific committee.ResultsScintigraphic images showed blood vessel activity in arteries and an early uptake in liver persisting over time. Median absorbed doses for 90-yttrium (mGy/MBq) were 3.5, 5.6, 3.8, 2.8, 0.5 to heart, liver, spleen, kidneys and bladder respectively. The uptake in lungs and bone marrow was negligible. No toxicity was observed.Conclusion90Y-Anti-FZD10-DTPA seems to be a well tolerated therapy, with potential efficiency and high tumour specificity. An ancillary study aims to analyze the correlation between predictive dosimetry from 111In imaging and actual dose delivered by the treatment from SPECT/CT and PETC/CT imaging of Yttrium-90.